Avanir Pharmaceuticals,
Inc. AVNR today announced the enrollment of the first patient in
study AVR-133. The study is a proof of concept, Phase II clinical trial
investigating the use of AVP-923 for the treatment of levodopa induced
dyskinesia (LID) in patients with Parkinson's disease (PD).
"This is an important study of a compound with multifaceted pharmacology for
the management of levodopa induced dyskinesia in Parkinson's disease," said
Anthony E. Lang, MD, Professor and Director of the Division of Neurology and
Chair for Parkinson's Disease Research at the University of Toronto. "Despite
advances in PD therapeutics, many patients still suffer with poorly controlled
dyskinesias, especially as they require higher doses of medications to
increase dopamine levels. Dyskinesias can not only be disabling but may also
limit the dose of effective medications that treat core symptoms of PD."
Top line data for this study is expected in the second half of calendar 2014.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in